Summary of Key Points
In the first half of 2026, the combined sales of Eli Lilly's tirzepatide (the diabetes version of Mounjaro and the weight loss version of Zepbound) and Novo Nordisk's semaglutides (Ozempic/Wegovy/Rybelsus) reached $45.2 billion, with annual sales expected to exceed $100 billion, setting a new record for revenue from a single therapeutic target in human pharmaceutical history. Tirzepatide, with its dual-target mechanism (GLP-1 + GIP), achieved a 88% year-on-year increase in sales, reaching $27.7 billion in the first half, significantly outpacing semaglutides' $17.5 billion. The gap between the two products widened from less than $2 billion in 2025 to $10.2 billion, establishing a stable duopoly with potential for change.
I. Sales Data: Half-Year Figures Surpass Many Companies' Annual Revenue; Growing Gap Between the Duopolists
How impressive are these sales figures?
- Tirzepatide's sales of $27.7 billion in half a year: This amount is equivalent to the annual revenue of over 90% of global pharmaceutical companies (with many well-known firms earning only $10-20 billion annually). The diabetes version generated $16.6 billion, and the weight loss version $11.1 billion, with growth primarily driven by the surge in demand for weight management solutions.
- Semaglutides' sales of $17.5 billion: Although the total is lower, the oral weight loss formulation sold $855 million as soon as it was launched, and the injectable version continues to show growth, with potential for improvement in the second half of the year.
- Annual Sales Target of $100 Billion: The combined annual sales of these two products are likely to exceed $100 billion for the first time, demonstrating that a single therapeutic target (GLP-1) can support such a large market, surpassing the peak of any previous "miracle drug" (such as statins or PD-1).
The more significant aspect is the change in their sales gap: Last year, the difference between tirzepatide and semaglutides was less than $2 billion, but this year it has widened to $10.2 billion—Eli Lilly's dual-target advantage (particularly effective for weight loss) has allowed it to capture a larger market share.
II. The GLP-1 Therapeutic Target: More Than Just Diabetes and Weight Loss—a "Master Switch" for Overall Metabolism
Why are these drugs so popular? Because the GLP-1 target is not just an ordinary diabetes medication; it acts as a "universal key" that regulates overall metabolism:
- Original Function: GLP-1, secreted in the intestines, stimulates insulin production and inhibits hormones that raise blood sugar levels, helping diabetics control their condition.
- Discoveried "Superpowers": Its receptors are found throughout the body, including the brain (regulating appetite), heart, kidneys, and liver. Activating GLP-1 is like pressing a "metabolic restructuring" button:
- Brain: It reduces food intake by increasing satiety and delaying gastric emptying; tirzepatide's dual-target effect leads to an average weight loss of 20-22 kilograms (compared to 15-18 kilograms with semaglutides).
- Heart: It lowers the risk of cardiovascular events such as heart attacks and strokes; semaglutides are the only weight loss drugs approved for this indication.
- Kidneys: It reduces the risk of kidney disease progression.
- Liver: It helps treat non-alcoholic steatohepatitis (MASH).
In short, GLP-1 addresses a range of metabolic issues related to diabetes, obesity, cardiovascular diseases, and kidney disease, which is why these drugs are so successful.
III. Expansion of Indications: From Diabetes and Weight Loss to a Range of Metabolic Disorders
The competitive focus has shifted from "who has the best weight loss effect" to "who can cover more diseases and patient populations":
- Tirzepatide (Eli Lilly): Approved in China for diabetes, obesity, and sleep apnea (common in overweight individuals), with additional applications for heart failure (also affecting obese patients) under review.
- Semaglutides (Novo Nordisk): Approved globally for kidney disease and non-alcoholic steatohepatitis, and an oral formulation has been launched (a boon for those who dread injections). The oral weight loss tablet sold $855 million in the first half of the year, and a combination drug with glucagon has been developed to compete more effectively.
In the future, these drugs may expand their use to conditions such as Alzheimer's disease and obstructive sleep apnea, essentially covering a wide range of metabolic disorders.
IV. The Duopoly: Why Others Cannot Enter the Market?
Entering the GLP-1 market is not easy due to high barriers:
1. Technical Barriers: For example, tirzepatide consists of 39 amino acids with fatty acid modifications, making it a complex molecule that few companies can produce.
2. Capacity Barriers: Building factories, purchasing freeze-drying equipment, and maintaining cold-chain logistics require significant investment (Eli Lilly invested $4.5 billion this year to expand production; Novo Nordisk also invested tens of billions).
3. Clinical Barriers: Large-scale trials cost millions and take years to complete (for instance, semaglutides' cardiovascular trial involved 17,000 participants over five years).
4. Patent Barriers: Core patents will expire in the 2030s; even if generic versions are developed, they must meet regulatory requirements.
In the Chinese market, tirzepatide's inclusion in medical insurance led to a 73% increase in sales (doubling in the second quarter), but domestic generics (such as those from East China Pharmaceutical and Federal Pharmaceutical) have started price competition, causing Novo Nordisk's sales in China to decline by 22.5%.
V. Future Challenges: Will There Be a Ceiling for Single-Target Therapies?
Although GLP-1 is currently a "miracle drug," there are concerns:
- Semaglutides' First Decline: The slowdown in sales this year suggests that the growth of single-target GLP-1 therapies may have reached its peak.
- Internal Disruption: Eli Lilly's triple-target drug (GLP-1 + GIP + glucagon) is expected to be launched in 2027, potentially competing with tirzepatide. Oral small-molecule GLP-1s (such as Eli Lilly's Orforglipron) could also challenge the market.
- External Competition: New metabolic targets (e.g., GIP or glucagon) may attract patients and split the market share.
However, for now, 2026 remains a "year of glory" for GLP-1, with these two drugs and their respective companies generating billions in revenue from a single therapeutic target, a remarkable achievement in the pharmaceutical industry.
Conclusion
2026 marks the year when GLP-1 became a true "miracle drug," transforming the pharmaceutical industry with its unique therapeutic potential. Despite future challenges, its current success is already worth documenting as an era where a single target has changed the course of medicine. GLP-1 is undoubtedly the star of this technological revolution.